Compare AstraZeneca plc (AZN) vs Burlington Stores Inc (BURL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Burlington Stores Inc — how do they compare? AstraZeneca plc trades at $158.58 (market cap $248.14B), while Burlington Stores Inc trades at $354.24 (market cap $22.59B). The key difference: AstraZeneca plc is far larger — about 11× Burlington Stores Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| AZN | BURL | |
|---|---|---|
Market Cap | $248.14B | $22.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $372.19 |
52-Week Low | $147.06 | $242.43 |
Enterprise Value | $275.41B | $27.71B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Burlington Stores (BURL) trades at $351.88, down 5.28% today but maintains strong technical support near $352. The company demonstrates robust fundamentals with revenue growth from $10.63B to $11.9B projected for 2026, net income margin expansion to 5.23%, and consistent earnings beats. Recent news highlights successful smaller-store strategy execution and multiple analyst upgrades. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $352 and resistance at $365.
BURL presents a compelling growth story with 94% analyst buy ratings and a $367 consensus target offering 4.3% upside. The retailer's margin expansion and store productivity improvements drive optimism, though competitive pressures and consumer spending sensitivity pose risks. Institutional ownership trends show mixed activity with recent insider selling offset by fund position increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
